GlassScriptPhysician profile
Shivani Patel
NPI 1891176244
$98,327.92
in general payments reported to CMS, 2019-2025
29 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.32 · 2020: $302 · 2021: $1,272 · 2022: $23K · 2023: $38K · 2024: $34K · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Consulting Fee: $9,250 · Food and Beverage: $6,411 · Travel and Lodging: $3,634 · Honoraria: $700 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,154.00 |
| Consulting Fee | $9,250.00 |
| Food and Beverage | $6,411.04 |
| Travel and Lodging | $3,634.48 |
| Honoraria | $700.00 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $53,807.58 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $17,968.24 | 2021-2025 | |
| Incyte Corporation | $7,819.89 | 2021-2025 | Opzelura |
| Amgen INC. | $4,832.27 | 2022-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $3,565.85 | 2023-2025 | Zoryve |
| Pfizer INC. | $2,797.37 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,916.05 | 2023-2024 | Vtama |
| Abbvie INC. | $1,649.33 | 2020-2025 | |
| Galderma Laboratories, L.P. | $924.11 | 2020-2025 | Dysport, Aklief, Nemluvio |
| Nobelpharma America, LLC | $749.94 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $582.75 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $376.23 | 2019-2025 | |
| Janssen Biotech, INC. | $337.84 | 2021-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $206.15 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $152.63 | 2019-2025 | Adbry, Anzupgo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $110.22 | 2021-2023 | Siliq |
| Janssen Scientific Affairs, LLC | $100.67 | 2021 | |
| Organon LLC | $56.89 | 2025 | Vtama |
| Ucb, INC. | $54.66 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.60 | 2022-2023 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $52.39 | 2022-2023 | Sotyktu |
| Almirall LLC | $43.51 | 2021-2023 | Seysara |
| Strata Skin Sciences, INC. | $35.14 | 2023 | Xtrac |
| Pierre Fabre Pharmaceuticals, INC. | $33.77 | 2024 | Hemangeol |
| Myovant Sciences INC. | $24.41 | 2022 | |
| Lnhc, INC | $21.67 | 2025 | Zelsuvmi |
| Krystal Biotech INC | $20.70 | 2024 | Vyjuvek |
| Journey Medical Corporation | $19.15 | 2022 | |
| Sebela Pharmaceuticals INC. | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivani Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.